[The oxygen kinetic effect of inhaled iloprost in pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension]. 2009

Na Cui, and Yuan-hua Yang, and Wan-mu Xie, and Zhan-hong Ma, and Ling Luo, and Chen Wang
Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, 100020, China.

OBJECTIVE To study the acute oxygen kinetic effect of inhaled iloprost in pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension. METHODS Twenty-two and 24 patients who were admitted to our hospital between June 2006 and January 2009 with confirmed diagnosis of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) respectively were enrolled to this study. During right heart catheterization, the hemodynamics and oxygen kinetics were monitored at baseline and after inhaling Iloprost (20 micrograms). RESULTS At baseline, the arterial partial pressure of oxygen (PaO2) was (63 +/- 10) mm Hg (1 mm Hg = 0.133 kPa) and (59 +/- 10) mm Hg respectively in PAH and CTEPH patients, and the oxygen delivery index (DO2I) and oxygen consumption index (VO2I) were (458 +/- 136) ml x min(-1) x m(-2) and (135 +/- 53) ml x min(-1) x m(-2) in PAH patients respectively, and (386 +/- 92) ml x min(-1) x m(-2) and (131 +/- 43) ml x min(-1) x m(-2) in CTEPH patients respectively. Three minutes after inhaling Iloprost, for PAH and CTEPH patients, the pulmonary shunt rate (Qs/Qt) all increased significantly (all P < 0.05, respectively) as well as the difference of oxygen partial pressure between pulmonary alveoli and artery (P[A-a]O2, all P < 0.05, respectively), and the arterial oxygen content (CaO2) all decreased significantly (all P < 0.05, respectively). The oxygenation parameters of mixed venous blood, oxygen extractive rate and DO2I did not change significantly, but VO2I declined to different extent. The extent of change after inhaling Iloprost for all oxygen kinetic parameters were similar between PAH and CTEPH patients. At baseline, mixed venous oxygen saturation (SvO2), venous oxygen content (CvO2) and DO2I in CTEPH patients were lower than those in PAH patients. After inhaling Iloprost, in CTEPH patients, PaO2, SvO2 and CvO2 were lower than those in PAH patients. CONCLUSIONS There were hypoxemia and abnormality of oxygen kinetics in PAH and CTEPH patients. After inhaling Iloprost, pulmonary shunt increased without improvement in oxygen kinetics. Oxygenation should be monitored closely and supply oxygen supplied for CTEPH when inhaling Iloprost.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010100 Oxygen An element with atomic symbol O, atomic number 8, and atomic weight [15.99903; 15.99977]. It is the most abundant element on earth and essential for respiration. Dioxygen,Oxygen-16,Oxygen 16
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D011651 Pulmonary Artery The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs. Arteries, Pulmonary,Artery, Pulmonary,Pulmonary Arteries
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Na Cui, and Yuan-hua Yang, and Wan-mu Xie, and Zhan-hong Ma, and Ling Luo, and Chen Wang
January 2008, Respiration; international review of thoracic diseases,
Na Cui, and Yuan-hua Yang, and Wan-mu Xie, and Zhan-hong Ma, and Ling Luo, and Chen Wang
July 2004, Archivos de bronconeumologia,
Na Cui, and Yuan-hua Yang, and Wan-mu Xie, and Zhan-hong Ma, and Ling Luo, and Chen Wang
September 2003, The Annals of thoracic surgery,
Na Cui, and Yuan-hua Yang, and Wan-mu Xie, and Zhan-hong Ma, and Ling Luo, and Chen Wang
September 2016, Pharmacotherapy,
Na Cui, and Yuan-hua Yang, and Wan-mu Xie, and Zhan-hong Ma, and Ling Luo, and Chen Wang
July 2013, Anaesthesia and intensive care,
Na Cui, and Yuan-hua Yang, and Wan-mu Xie, and Zhan-hong Ma, and Ling Luo, and Chen Wang
November 2007, Cardiovascular ultrasound,
Na Cui, and Yuan-hua Yang, and Wan-mu Xie, and Zhan-hong Ma, and Ling Luo, and Chen Wang
January 2005, The Annals of pharmacotherapy,
Na Cui, and Yuan-hua Yang, and Wan-mu Xie, and Zhan-hong Ma, and Ling Luo, and Chen Wang
January 2004, Drugs,
Na Cui, and Yuan-hua Yang, and Wan-mu Xie, and Zhan-hong Ma, and Ling Luo, and Chen Wang
August 2005, American journal of respiratory and critical care medicine,
Na Cui, and Yuan-hua Yang, and Wan-mu Xie, and Zhan-hong Ma, and Ling Luo, and Chen Wang
August 2002, The New England journal of medicine,
Copied contents to your clipboard!